[go: up one dir, main page]

UA94734C2 - ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ - Google Patents

ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ

Info

Publication number
UA94734C2
UA94734C2 UAA200810923A UAA200810923A UA94734C2 UA 94734 C2 UA94734 C2 UA 94734C2 UA A200810923 A UAA200810923 A UA A200810923A UA A200810923 A UAA200810923 A UA A200810923A UA 94734 C2 UA94734 C2 UA 94734C2
Authority
UA
Ukraine
Prior art keywords
amyloid peptide
binds
therapeutic
antibodiy
antibody
Prior art date
Application number
UAA200810923A
Other languages
English (en)
Ukrainian (uk)
Inventor
Стефан Энтони Бурбидг
Джонатан Генри Эллис
Сюзанна К. Форд
Волкер Гермащевски
Юмеш Кумар
Крен Луис Филпотт
Петер Эрнест Соден
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of UA94734C2 publication Critical patent/UA94734C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Изобретение относится к терапевтическому антителу, которое связывается с β-амилоидным пептидом, фармацевтической композиции, которая его содержит, и применения данного антитела в производстве лекарственного средства для лечения заболевания, связанного с β-амилоидным пептидом.
UAA200810923A 2006-03-30 2007-03-27 ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ UA94734C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78758806P 2006-03-30 2006-03-30

Publications (1)

Publication Number Publication Date
UA94734C2 true UA94734C2 (ru) 2011-06-10

Family

ID=38284050

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200810923A UA94734C2 (ru) 2006-03-30 2007-03-27 ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ

Country Status (32)

Country Link
US (3) US8227576B2 (ru)
EP (2) EP2177536B1 (ru)
JP (1) JP5103466B2 (ru)
KR (2) KR101263294B1 (ru)
CN (2) CN103539857A (ru)
AR (1) AR060332A1 (ru)
AT (1) ATE451392T1 (ru)
AU (1) AU2007233831B2 (ru)
BR (1) BRPI0709246A2 (ru)
CA (1) CA2647808C (ru)
CR (1) CR10347A (ru)
CY (1) CY1109877T1 (ru)
DE (1) DE602007003703D1 (ru)
DK (2) DK1996621T3 (ru)
EA (1) EA015654B9 (ru)
ES (2) ES2338179T3 (ru)
HR (2) HRP20100115T1 (ru)
IL (1) IL193695A (ru)
JO (1) JO2576B1 (ru)
MA (1) MA30337B1 (ru)
MX (1) MX2008012483A (ru)
MY (1) MY149630A (ru)
NO (1) NO20083793L (ru)
NZ (1) NZ571038A (ru)
PE (1) PE20080181A1 (ru)
PL (2) PL2177536T3 (ru)
PT (2) PT2177536E (ru)
SI (2) SI1996621T1 (ru)
TW (1) TWI385179B (ru)
UA (1) UA94734C2 (ru)
WO (1) WO2007113172A2 (ru)
ZA (1) ZA200807911B (ru)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CN1747747B (zh) 2003-01-06 2012-09-05 安吉奥开米公司 作为穿过血脑屏障的载体的抑酶肽及类似物
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
EP1976877B2 (en) 2005-11-30 2016-10-05 AbbVie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TWI551607B (zh) 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
PT2182983E (pt) * 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
ES2473623T3 (es) * 2007-08-20 2014-07-07 Glaxo Group Limited Procedimiento de producción
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
EP2205631B1 (en) * 2007-10-05 2016-11-23 Genentech, Inc. Methods and compositions for diagnosis and treatment of amyloidosis
SG10201505369QA (en) 2007-10-05 2015-08-28 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
KR101280704B1 (ko) * 2007-10-12 2013-07-01 에프. 호프만-라 로슈 아게 다수의 핵산으로부터의 단백질 발현
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2222700A2 (en) * 2007-11-27 2010-09-01 Medtronic, Inc. Humanized anti-amyloid beta antibodies
ES2525704T3 (es) * 2007-12-11 2014-12-29 Glaxo Group Limited Proteínas de unión a antígenos
CA2709354C (en) 2007-12-21 2014-06-17 Amgen Inc. Anti-amyloid antibodies and uses thereof
AR071634A1 (es) 2008-05-06 2010-06-30 Glaxo Group Ltd Nanoparticulas para encapsulacion de agentes biologicamente activos
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010063122A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
IN2012DN00248A (ru) 2009-07-02 2015-05-01 Angiochem Inc
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2308897A1 (en) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
MX2012009460A (es) 2010-03-03 2012-09-12 Boehringer Ingelheim Int Polipeptidos biparatopicos de union abeta.
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2011149461A1 (en) * 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
KR101713365B1 (ko) 2010-07-30 2017-03-08 에이씨 이뮨 에스.에이. 안전하고 기능적인 인간화 항 베타-아밀로이드 항체
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
SI2646470T1 (sl) * 2010-11-30 2017-05-31 F. Hoffmann-La Roche Ag Protitelesa proti receptorjem antitransferina in njihova uporaba za prenos terapevtskega enoverižnega variabilnega fragmenta (scfv) prek krvno-možganske pregrade
ES2714692T3 (es) 2011-01-31 2019-05-29 Tau Bio Logic Corp Tratamiento de tauopatías
CA2833019A1 (en) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
GB201113570D0 (en) * 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
WO2013177062A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
JP2016529482A (ja) 2013-06-19 2016-09-23 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 新規アッセイ
CN104558172A (zh) * 2015-01-04 2015-04-29 东南大学 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用
ES2826827T3 (es) 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
WO2017072090A1 (en) * 2015-10-27 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Combination therapy
US11530257B2 (en) * 2017-06-29 2022-12-20 The Trustees Of Columbia University In The City Of New York Chimeric antibodies for treatment of amyloid deposition diseases
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
JP7436449B2 (ja) 2018-07-17 2024-02-21 ジエンス ヘンルイ メデイシンカンパニー リミテッド 抗ａベータ抗体、その抗原結合フラグメントおよびそれらの用途
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
US12435129B2 (en) 2020-07-23 2025-10-07 Othair Prothena Limited Anti-Aβ antibodies
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114591918B (zh) * 2022-05-07 2022-07-26 北京第一生物化学药业有限公司 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途
CN114591917B (zh) * 2022-05-07 2022-09-02 北京第一生物化学药业有限公司 产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN118638219B (zh) * 2024-08-19 2024-11-22 成都迈科康生物科技有限公司 一种抗轮状病毒vp8蛋白的抗体或其抗原结合片段、抗体偶联物、核酸、载体、细胞及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811517A (en) * 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
PT994728E (pt) * 1997-04-09 2008-11-11 Intellect Neurosciences Inc Anticorpos recombinantes específicos contra terminações beta-amilóide, codificação por adn e métodos de utilização destes
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
JP2002530122A (ja) * 1998-11-25 2002-09-17 サイオス インコーポレイテッド アミロイド関連疾患の予防及び治療
KR100767146B1 (ko) * 2000-02-24 2007-10-15 워싱톤 유니버시티 Ａβ 펩티드를 격리시키는 인간화 항체
AU2002239766B9 (en) * 2000-11-03 2007-04-05 The J. David Gladstone Institutes Methods of treating disorders related to apoE
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
ITTO20020867A1 (it) * 2002-10-08 2004-04-09 Pro Cord Spa Schienale di sedia.
JP2006519762A (ja) * 2002-10-09 2006-08-31 ライナット ニューロサイエンス コーポレイション アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法

Also Published As

Publication number Publication date
TWI385179B (zh) 2013-02-11
EP2177536A1 (en) 2010-04-21
JP2009531380A (ja) 2009-09-03
PE20080181A1 (es) 2008-03-16
PT2177536E (pt) 2014-08-22
ATE451392T1 (de) 2009-12-15
WO2007113172A2 (en) 2007-10-11
PL2177536T3 (pl) 2014-11-28
EA015654B1 (ru) 2011-10-31
BRPI0709246A2 (pt) 2011-07-12
MY149630A (en) 2013-09-13
EP2177536B1 (en) 2014-06-04
US20110142824A1 (en) 2011-06-16
JP5103466B2 (ja) 2012-12-19
CR10347A (es) 2008-10-29
HRP20100115T1 (hr) 2010-04-30
ES2338179T3 (es) 2010-05-04
US8227576B2 (en) 2012-07-24
HK1122311A1 (en) 2009-05-15
IL193695A0 (en) 2011-08-01
WO2007113172A3 (en) 2007-11-29
EP1996621A2 (en) 2008-12-03
CN101415729B (zh) 2013-09-04
AU2007233831A1 (en) 2007-10-11
SI2177536T1 (sl) 2014-09-30
DK2177536T3 (da) 2014-07-14
KR101263294B1 (ko) 2013-06-04
JO2576B1 (en) 2011-02-27
CA2647808C (en) 2015-11-17
CN103539857A (zh) 2014-01-29
HK1138015A1 (en) 2010-08-13
US9193784B2 (en) 2015-11-24
MX2008012483A (es) 2008-10-10
CA2647808A1 (en) 2007-10-11
KR20120093400A (ko) 2012-08-22
AR060332A1 (es) 2008-06-11
HRP20140618T1 (hr) 2014-08-15
PT1996621E (pt) 2010-03-08
ZA200807911B (en) 2009-11-25
ES2484967T3 (es) 2014-08-12
NO20083793L (no) 2008-10-13
EA015654B9 (ru) 2012-01-30
SI1996621T1 (sl) 2010-04-30
CY1109877T1 (el) 2014-09-10
PL1996621T3 (pl) 2010-05-31
DK1996621T3 (da) 2010-04-19
DE602007003703D1 (de) 2010-01-21
TW200815466A (en) 2008-04-01
AU2007233831B2 (en) 2013-02-14
NZ571038A (en) 2011-03-31
CN101415729A (zh) 2009-04-22
IL193695A (en) 2012-05-31
US20160024197A1 (en) 2016-01-28
US20140050719A1 (en) 2014-02-20
EP1996621B1 (en) 2009-12-09
KR20080113273A (ko) 2008-12-29
MA30337B1 (fr) 2009-04-01
EA200801842A1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
TW200744642A (en) Novel peptides for use in the treatment of obesity
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
UA105210C2 (ru) Противораковая вакцина и ее применение
WO2008087186A3 (en) Peptides for use in the treatment of obesity
IL201479A (en) Use of tapentadol for the preparation of pain medication
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
WO2008087190A3 (en) Use of peptides in combination with surgical intervention for the treatment of obesity
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
EA200802208A1 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
PH12013500108A1 (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
WO2008087188A3 (en) Peptides for use in the treatment of obesity
ATE543804T1 (de) Neue verbindungen
NZ628513A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
IL205290A (en) A variant of human neurorthin protein, or its active biological part, containing medicinal preparations, and its use in the preparation of therapeutic drugs
WO2008087189A3 (en) Peptides for use in the treatment of obesity
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease